Acadia Pharmaceuticals
ACAD
ACAD
196 hedge funds and large institutions have $3.69B invested in Acadia Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 75 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 75
66% less call options, than puts
Call options by funds: $38.8M | Put options by funds: $113M
Holders
196
Holding in Top 10
3
Calls
$38.8M
Puts
$113M
Top Buyers
| 1 | +$97.1M | |
| 2 | +$42.4M | |
| 3 | +$26.7M | |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$19.1M |
| 5 |
D.E. Shaw & Co
New York
|
+$12.3M |
Top Sellers
| 1 | -$28.5M | |
| 2 | -$16M | |
| 3 | -$13.4M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$11.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.5M |